|
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
RECRUITINGEarly 1Sponsored by Massachusetts General Hospital
Actively Recruiting
PhaseEarly 1
SponsorMassachusetts General Hospital
Started2026-02-04
Est. completion2030-12
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07358195
Summary
The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.
Eligibility
Age: 18 Years – 70 YearsHealthy volunteers accepted
Recipient Inclusion Criteria: * Patient ages 18-70 * Underlying hematological malignancy which is deemed as being potentially curable with allogeneic bone marrow or PBSC transplantation by the BMT voting team. * Hematological malignancies include, but are not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS. Patient should be in a partial (PR) or complete remission (CR) at the time of the transplant. * Existence of an HLA-matched or haploidentical relative who passes standard donor evaluations for bone marrow and kidney donation * LVEF \> 40% as measured by echocardiography or MUGA * FEV1, FVC, and DLCO \> 50% of predicted as measured by standard PFTs * Total bilirubin \< 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all \< 5x institutions upper limit of normal * ABO compatibility in the host vs. graft direction * Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant. * Participants should be on dialysis or have a CrCl ≤ 35 ml/min * Life expectancy greater than 6 months * Recipient ability to understand and provide informed consent Donor Inclusion Criteria: * HLA matched or haploidentical relative as defined by 3/6, 4/6, or 5/6 HLA-matched at HLA -A, -B, or -DRB1 who is 18-70 years of age * ECOG performance status 0 or 1 * Excellent health per conventional pre-donor history (medical and psychosocial evaluation) • Acceptable laboratory parameters (hematology in normal or near-normal range; liver function \< 3 times the upper limit of normal and normal creatinine) * Compatible ABO blood group * Negative donor lymphocyte cross match * No positive testing for active viral infection (Hepatitis B, Hepatitis C, HIV) * Donor ability to understand and provide informed consent * Meets standard institutional criteria for both bone marrow or peripheral blood stem cell (PBSC) and kidney donation Exclusion Criteria: * Active serious infection * Participation in other investigational drug use at the time of enrollment * Positivity for active infection with HIV, HCV, or HBV * ABO blood group incompatibility in the host-vs-graft direction
Conditions6
CancerHematologic CancerKidney Failure, ChronicStem Cell TransplantStem Cell Transplant ComplicationsTolerance
Interventions1
Locations1 site
Massachusetts General Hospital
Find trials near these locations
Related trials
- A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia — Maxinovel Pty., Ltd.
- A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL — German CLL Study Group
- A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia — Sichuan Baili Pharmaceutical Co., Ltd.
- A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) — Dizal Pharmaceuticals
- A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia — Shanghai Tong Ren Hospital
- A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML — Stichting Hemato-Oncologie voor Volwassenen Nederland
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL — Institute of Hematology & Blood Diseases Hospital, China
- AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission — The First Affiliated Hospital of Soochow University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseEarly 1
SponsorMassachusetts General Hospital
Started2026-02-04
Est. completion2030-12
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07358195